A Site-Specific B7-H3 Targeting Antibody-Drug Conjugate for Cancer Therapy
New weapon for precision anticancer drug-antibody-drug conjugates composed target-specific antibodies and highly potent chemo-agents precisely eliminate the tumors, which have become a hot area in the current anti-cancer drug development. B7-H3 is abundantly expressed in various cancer tissues and represents a promising target in this field. The Development Center for Biotechnology has successfully developed a novel and site-specific B7-H3-targeting antibody-drug conjugate candidate, DCBAD2303, by using the proprietary tri-mannosyl conjugation platform. DCBAD2303 exhibits high affinity for B7-H3, selective cytotoxicity to B7-H3-positive cancer cells, and significant anti-cancer efficacy. Hence, these characteristics demonstrate that DCBAD2303 has clinical development potential for treating B7-H3-positive cancers.
Technical features:
・Fully human antibody with unique CDR sequences
・Site specific conjugated ADC drug with uniform DAR via proprietary trimannosyl-based conjugation platform
・Significant anti-tumor activity in mice bearing regular tumor or large tumor
With over 400 dedicated researchers and state-of-the-art facilities , the Development Center for Biotechnology (DCB) specializes in developing biologics and small molecule drugs , botanical drugs , as well as technologies required for preclinical testing. Our expertise arises from the integration of a number of diverse disciplines , including biology , chemistry , protein purification and engineering , as well as analytical and quality assurance. Established in 1984 by Taiwan's Ministry of Economic Affairs (MOEA) , Department of Industrial Technology (DoIT) , DCB was initially tasked with establishing the biotechnology industry in Taiwan. Through strategic global alliances and technology transfer agreements , DCB has successfully fostered the development of a complete biotech infrastructure and value chain , as well as a diverse array of applications for use by the private sector. As a result , DCB has become one of Taiwan's most important research institutes. DCB's mission is to facilitate the ongoing growth and development Taiwan's biotechnology industry. To this end , we strive to act as the industry's partner , coordinating resources among government , academia and private companies. DCB remains a key force in building and upgrading Taiwan's biomedical infrastructure, developing key technologies , and growing Taiwan's professional workforce. Our ultimate aim is to improve the quality of life for the people of Taiwan and the world. To this end , DCB fosters international partnerships and collaborations with research institutes and global biopharmaceuticals throughout Asia and the world.
Name:
Phone:
Address:No.107, Ln. 130, Sec. 1, Academia Rd., Nangang Dist., Taipei City 11571, Taiwan, R.O.C.
GLUT Targeting Small Molecule Drug Conjugation for Cancer Therapy
DBPR376-Targeting Small Molecule Mertansine Conjugate for Cancer Treatment(SMDC)
DBPR22998:A Potent QPCTL (IsoQC) Inhibitor Targeting CD47-SIRP⍺ Axis for Cancer Immunotherapy
DBPR22998:A Potent QPCTL (IsoQC) Inhibitor Targeting CD47-SIRP⍺ Axis for Cancer Immunotherapy
Technology maturity:Experiment stage
Exhibiting purpose:Technology transactions、Patent transactions、Product promotion、Display of scientific results
Trading preferences:Negotiate by self
Coming soon!